Cartesian Therapeutics, Inc. (RNAC) Stock Forecast
RNAC analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.86 / 5 from 7 analysts
- Price target
- $33.67 average of analyst targets
- Upside to target
- +436.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.02
- 52-week range
- $5.84 – $10.59
RNAC analyst ratings
7 analystsNumber of analysts at each rating.
RNAC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RNAC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.01 | −$1.01 | −$1.01 | −$0.73 | −38.2% | 1 |
| Current fiscal year (2026) | −$2.78 | −$2.78 | −$2.78 | −$4.99 | +44.3% | 1 |
| Next fiscal year (2027) | −$3.81 | −$3.81 | −$3.81 | −$2.78 | −37.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RNAC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $121,430 | $0 | $300,000 | −73.1% | 7 |
| Current fiscal year (2026) | $419,140 | $78,000 | $1.0M | −85.0% | 7 |
| Next fiscal year (2027) | $285,710 | $0 | $1.0M | −31.8% | 7 |
RNAC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RNAC revenue: reported and forecast
RNAC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.69 | −$0.69 | −$0.69 | −$1.01 | +80.4% | 0 up · 1 down |
| Current fiscal year (2026) | −$3.01 | −$3.35 | −$3.35 | −$3.35 | −$2.78 | −7.6% | 0 up · 1 down |
| Next fiscal year (2027) | −$2.13 | −$2.68 | −$2.68 | −$2.68 | −$3.81 | +78.9% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RNAC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RNAC beat in 8 of 12.
What analysts expect from RNAC
7 analysts cover Cartesian Therapeutics; their consensus rating is strong buy (4.86 on a 1–5 scale, where 5 is a strong buy). The average price target is $33.67, 436.9% above the latest close of $6.27. Analysts expect earnings of −$2.78 per share for 2026, +44.3% from a year earlier. For 2027 the average estimate is −$3.81 per share on revenue of $0.3 million. Cartesian Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: RNAC income statement, RNAC key metrics, RNAC chart. See the RNAC stock overview for the latest quote and news.
RNAC forecast FAQ
What is Cartesian Therapeutics's price target?
The average analyst price target for Cartesian Therapeutics is $33.67, 436.9% above the latest close of $6.27.
Is Cartesian Therapeutics a buy, hold or sell?
Of 7 analysts covering Cartesian Therapeutics, 6 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cartesian Therapeutics's EPS forecast?
Analysts forecast −$2.78 per share for 2026 (range −$2.78 to −$2.78); for 2027 the estimate is −$3.81.
What is Cartesian Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.4 million, growth of −85.0%; for 2027 it is $0.3 million.
When does Cartesian Therapeutics report earnings?
Cartesian Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-1.02.
Does Cartesian Therapeutics usually beat earnings estimates?
Cartesian Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.